 Viralkumar Shah
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 83 | 2024 | 3254 | 13.620 |
Why?
| | Blood Glucose | 49 | 2024 | 1827 | 6.100 |
Why?
| | Blood Glucose Self-Monitoring | 39 | 2024 | 505 | 6.030 |
Why?
| | Hypoglycemic Agents | 36 | 2023 | 1011 | 5.510 |
Why?
| | Hypoglycemia | 21 | 2023 | 386 | 5.290 |
Why?
| | Insulin | 32 | 2023 | 2080 | 3.820 |
Why?
| | Diabetes Mellitus, Type 2 | 16 | 2023 | 2087 | 3.210 |
Why?
| | Insulin Infusion Systems | 19 | 2023 | 298 | 3.130 |
Why?
| | Osteoporotic Fractures | 6 | 2020 | 54 | 2.720 |
Why?
| | Pancreas, Artificial | 4 | 2023 | 68 | 2.650 |
Why?
| | Bone Density | 10 | 2022 | 432 | 2.380 |
Why?
| | Biosimilar Pharmaceuticals | 4 | 2023 | 25 | 2.270 |
Why?
| | Diabetic Ketoacidosis | 4 | 2022 | 161 | 2.220 |
Why?
| | Fractures, Bone | 7 | 2020 | 367 | 1.860 |
Why?
| | Insulin Aspart | 4 | 2023 | 26 | 1.780 |
Why?
| | Adult | 63 | 2024 | 30371 | 1.670 |
Why?
| | Hyperparathyroidism, Primary | 5 | 2014 | 5 | 1.570 |
Why?
| | Hyperglycemia | 7 | 2022 | 292 | 1.430 |
Why?
| | Humans | 105 | 2024 | 114039 | 1.420 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 898 | 1.350 |
Why?
| | Diabetes Complications | 4 | 2020 | 208 | 1.320 |
Why?
| | Insulin Glargine | 5 | 2023 | 72 | 1.320 |
Why?
| | Femur Neck | 4 | 2022 | 59 | 1.260 |
Why?
| | Young Adult | 31 | 2023 | 10442 | 1.100 |
Why?
| | Cannabis | 3 | 2022 | 383 | 1.010 |
Why?
| | Marijuana Abuse | 2 | 2019 | 211 | 0.990 |
Why?
| | Middle Aged | 38 | 2023 | 26601 | 0.990 |
Why?
| | Glucose | 6 | 2023 | 899 | 0.970 |
Why?
| | Male | 48 | 2024 | 55392 | 0.900 |
Why?
| | Female | 50 | 2024 | 59321 | 0.900 |
Why?
| | Registries | 10 | 2021 | 1764 | 0.870 |
Why?
| | Insulin, Long-Acting | 3 | 2021 | 53 | 0.860 |
Why?
| | Cardiovascular Diseases | 6 | 2022 | 1726 | 0.850 |
Why?
| | Sweetening Agents | 1 | 2023 | 37 | 0.850 |
Why?
| | Bone and Bones | 2 | 2023 | 277 | 0.840 |
Why?
| | Bone Remodeling | 2 | 2020 | 65 | 0.820 |
Why?
| | Vitamin D | 3 | 2014 | 340 | 0.810 |
Why?
| | Gastroparesis | 2 | 2019 | 8 | 0.810 |
Why?
| | Risk Factors | 16 | 2022 | 8614 | 0.790 |
Why?
| | Diabetic Retinopathy | 1 | 2024 | 149 | 0.790 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.780 |
Why?
| | RNAi Therapeutics | 1 | 2021 | 3 | 0.780 |
Why?
| | Adolescent | 26 | 2023 | 17798 | 0.780 |
Why?
| | Hyperoxaluria, Primary | 1 | 2021 | 14 | 0.770 |
Why?
| | Insulins | 1 | 2022 | 32 | 0.770 |
Why?
| | Automobile Driving | 1 | 2023 | 129 | 0.740 |
Why?
| | Osteoporosis | 3 | 2020 | 224 | 0.710 |
Why?
| | Incretins | 1 | 2020 | 15 | 0.710 |
Why?
| | Self-Management | 2 | 2020 | 126 | 0.700 |
Why?
| | Blindness | 1 | 2020 | 36 | 0.690 |
Why?
| | Bone Resorption | 1 | 2020 | 73 | 0.680 |
Why?
| | Age Factors | 6 | 2020 | 2885 | 0.660 |
Why?
| | Hip Fractures | 1 | 2020 | 75 | 0.660 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2019 | 36 | 0.630 |
Why?
| | Osteogenesis | 1 | 2020 | 181 | 0.610 |
Why?
| | Self Care | 2 | 2018 | 350 | 0.610 |
Why?
| | Parathyroid Hormone | 4 | 2014 | 96 | 0.590 |
Why?
| | Bone Diseases | 1 | 2018 | 57 | 0.590 |
Why?
| | Quality of Life | 3 | 2023 | 2343 | 0.580 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 248 | 0.580 |
Why?
| | Absorptiometry, Photon | 4 | 2022 | 224 | 0.560 |
Why?
| | Calcium | 6 | 2014 | 1089 | 0.550 |
Why?
| | Drugs, Investigational | 1 | 2017 | 30 | 0.540 |
Why?
| | Marijuana Smoking | 1 | 2019 | 224 | 0.520 |
Why?
| | Accidental Falls | 1 | 2018 | 151 | 0.520 |
Why?
| | Fractures, Spontaneous | 1 | 2015 | 13 | 0.510 |
Why?
| | Vitamin D Deficiency | 2 | 2014 | 158 | 0.490 |
Why?
| | Child | 19 | 2023 | 18400 | 0.480 |
Why?
| | Aged | 19 | 2022 | 18969 | 0.470 |
Why?
| | Gallstones | 1 | 2014 | 28 | 0.450 |
Why?
| | Suicide | 1 | 2020 | 507 | 0.450 |
Why?
| | Glucose Intolerance | 1 | 2015 | 137 | 0.440 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 43 | 0.430 |
Why?
| | Cross-Sectional Studies | 7 | 2023 | 4400 | 0.430 |
Why?
| | Pancreatitis | 1 | 2014 | 105 | 0.420 |
Why?
| | Bone Diseases, Metabolic | 3 | 2019 | 53 | 0.390 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 169 | 0.380 |
Why?
| | Autoimmune Diseases | 1 | 2015 | 381 | 0.380 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 4595 | 0.380 |
Why?
| | Diabetic Angiopathies | 3 | 2020 | 246 | 0.380 |
Why?
| | Prospective Studies | 6 | 2023 | 6195 | 0.380 |
Why?
| | Sex Factors | 4 | 2020 | 1706 | 0.360 |
Why?
| | Obesity | 1 | 2023 | 2505 | 0.350 |
Why?
| | Retrospective Studies | 10 | 2024 | 12520 | 0.350 |
Why?
| | Benchmarking | 2 | 2022 | 161 | 0.340 |
Why?
| | Treatment Outcome | 8 | 2020 | 9049 | 0.320 |
Why?
| | Meals | 2 | 2020 | 105 | 0.310 |
Why?
| | Autoantibodies | 2 | 2018 | 1347 | 0.310 |
Why?
| | Prevalence | 5 | 2023 | 2246 | 0.300 |
Why?
| | Phenotype | 1 | 2015 | 2784 | 0.290 |
Why?
| | Body Mass Index | 3 | 2020 | 1957 | 0.280 |
Why?
| | Reference Values | 2 | 2019 | 739 | 0.280 |
Why?
| | Risk Assessment | 3 | 2020 | 2958 | 0.280 |
Why?
| | India | 3 | 2015 | 134 | 0.260 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2384 | 0.250 |
Why?
| | United States | 8 | 2020 | 12136 | 0.250 |
Why?
| | Case-Control Studies | 4 | 2020 | 3003 | 0.230 |
Why?
| | Phosphates | 3 | 2014 | 155 | 0.230 |
Why?
| | Artificial Organs | 1 | 2023 | 1 | 0.220 |
Why?
| | Germany | 2 | 2020 | 84 | 0.220 |
Why?
| | Cross-Over Studies | 3 | 2019 | 439 | 0.210 |
Why?
| | Glycemic Index | 1 | 2022 | 20 | 0.210 |
Why?
| | History, 20th Century | 2 | 2014 | 265 | 0.210 |
Why?
| | Insulin Lispro | 1 | 2022 | 34 | 0.200 |
Why?
| | Minority Groups | 2 | 2023 | 223 | 0.200 |
Why?
| | Follow-Up Studies | 2 | 2022 | 4392 | 0.200 |
Why?
| | Biomarkers | 3 | 2023 | 3397 | 0.200 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 27 | 0.200 |
Why?
| | Sex Characteristics | 2 | 2018 | 636 | 0.190 |
Why?
| | Gastric Emptying | 1 | 2021 | 39 | 0.190 |
Why?
| | Computer Systems | 2 | 2018 | 46 | 0.190 |
Why?
| | Calibration | 2 | 2018 | 125 | 0.190 |
Why?
| | Diabetic Neuropathies | 1 | 2022 | 78 | 0.180 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2020 | 2 | 0.180 |
Why?
| | Regression Analysis | 2 | 2020 | 945 | 0.180 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2020 | 14 | 0.180 |
Why?
| | Energy Intake | 1 | 2023 | 427 | 0.180 |
Why?
| | Austria | 1 | 2020 | 2 | 0.180 |
Why?
| | Psychometrics | 2 | 2021 | 608 | 0.180 |
Why?
| | Skiing | 1 | 2021 | 42 | 0.180 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6306 | 0.170 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 20 | 0.170 |
Why?
| | RNA Interference | 1 | 2021 | 431 | 0.170 |
Why?
| | Reproducibility of Results | 4 | 2021 | 2764 | 0.170 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 134 | 0.170 |
Why?
| | Postprandial Period | 1 | 2020 | 87 | 0.160 |
Why?
| | C-Peptide | 1 | 2020 | 138 | 0.160 |
Why?
| | Insulin Antibodies | 1 | 2020 | 102 | 0.160 |
Why?
| | Bone Development | 1 | 2019 | 47 | 0.160 |
Why?
| | Fatal Outcome | 1 | 2020 | 281 | 0.160 |
Why?
| | Radius | 1 | 2019 | 33 | 0.160 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2021 | 17 | 0.160 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 200 | 0.160 |
Why?
| | Social Class | 1 | 2020 | 205 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1204 | 0.160 |
Why?
| | Healthy Volunteers | 1 | 2019 | 191 | 0.160 |
Why?
| | Infusion Pumps, Implantable | 1 | 2018 | 20 | 0.160 |
Why?
| | Cancellous Bone | 1 | 2018 | 20 | 0.150 |
Why?
| | Methyldopa | 1 | 2018 | 7 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2020 | 200 | 0.150 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 207 | 0.150 |
Why?
| | Postmenopause | 1 | 2020 | 301 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 40 | 0.150 |
Why?
| | Health Behavior | 1 | 2023 | 701 | 0.140 |
Why?
| | Time Factors | 3 | 2023 | 6077 | 0.140 |
Why?
| | Tibia | 1 | 2019 | 166 | 0.140 |
Why?
| | Sensitivity and Specificity | 1 | 2022 | 1690 | 0.140 |
Why?
| | Pelvic Bones | 1 | 2020 | 126 | 0.140 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 174 | 0.140 |
Why?
| | Pregnancy in Diabetics | 1 | 2018 | 82 | 0.140 |
Why?
| | Glucagon | 1 | 2017 | 92 | 0.140 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 103 | 0.140 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 949 | 0.140 |
Why?
| | Antigen Presentation | 1 | 2018 | 188 | 0.140 |
Why?
| | Uric Acid | 1 | 2018 | 148 | 0.140 |
Why?
| | Biosensing Techniques | 1 | 2018 | 100 | 0.140 |
Why?
| | Computer-Aided Design | 1 | 2017 | 38 | 0.140 |
Why?
| | Hormones | 1 | 2017 | 132 | 0.140 |
Why?
| | Health Personnel | 1 | 2022 | 569 | 0.140 |
Why?
| | Antibody Formation | 1 | 2018 | 266 | 0.140 |
Why?
| | Circadian Rhythm | 1 | 2019 | 356 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 247 | 0.130 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 317 | 0.130 |
Why?
| | Drug Design | 1 | 2017 | 147 | 0.130 |
Why?
| | Alkaline Phosphatase | 2 | 2014 | 142 | 0.130 |
Why?
| | Drug Overdose | 1 | 2020 | 292 | 0.130 |
Why?
| | Energy Metabolism | 1 | 2020 | 727 | 0.120 |
Why?
| | Diabetic Nephropathies | 1 | 2018 | 234 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2018 | 459 | 0.120 |
Why?
| | Parathyroidectomy | 1 | 2014 | 7 | 0.110 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.110 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 7 | 0.110 |
Why?
| | Allylamine | 1 | 2013 | 7 | 0.110 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 10 | 0.110 |
Why?
| | Bromocriptine | 1 | 2013 | 26 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2537 | 0.110 |
Why?
| | Insulin Detemir | 1 | 2013 | 7 | 0.110 |
Why?
| | History, 21st Century | 1 | 2014 | 160 | 0.110 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2014 | 53 | 0.110 |
Why?
| | Insulin, Isophane | 1 | 2013 | 17 | 0.110 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 44 | 0.110 |
Why?
| | Bionics | 2 | 2023 | 11 | 0.110 |
Why?
| | Recurrence | 1 | 2016 | 925 | 0.110 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 98 | 0.110 |
Why?
| | Islet Amyloid Polypeptide | 1 | 2013 | 47 | 0.110 |
Why?
| | Cohort Studies | 2 | 2020 | 4882 | 0.110 |
Why?
| | Parathyroid Neoplasms | 1 | 2012 | 13 | 0.100 |
Why?
| | Abdominal Pain | 1 | 2014 | 134 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 158 | 0.100 |
Why?
| | Pregnancy | 2 | 2021 | 5499 | 0.100 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2013 | 100 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2013 | 142 | 0.100 |
Why?
| | Dogs | 1 | 2013 | 331 | 0.100 |
Why?
| | Hypoparathyroidism | 1 | 2012 | 4 | 0.100 |
Why?
| | Hemoglobins | 1 | 2014 | 308 | 0.100 |
Why?
| | Leptin | 1 | 2013 | 210 | 0.100 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2012 | 65 | 0.100 |
Why?
| | Algorithms | 2 | 2018 | 1469 | 0.090 |
Why?
| | Cholelithiasis | 1 | 2011 | 31 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 582 | 0.090 |
Why?
| | Swine | 1 | 2013 | 687 | 0.090 |
Why?
| | Animals | 4 | 2018 | 31565 | 0.090 |
Why?
| | Consensus | 2 | 2023 | 532 | 0.090 |
Why?
| | Adenoma | 1 | 2012 | 187 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1735 | 0.090 |
Why?
| | Heart Failure | 1 | 2023 | 1958 | 0.090 |
Why?
| | Metformin | 1 | 2013 | 274 | 0.090 |
Why?
| | Exercise | 1 | 2020 | 1642 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4090 | 0.080 |
Why?
| | Pilot Projects | 3 | 2021 | 1360 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1168 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1080 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2023 | 94 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2022 | 33 | 0.050 |
Why?
| | Needles | 1 | 2022 | 49 | 0.050 |
Why?
| | Off-Label Use | 1 | 2021 | 51 | 0.050 |
Why?
| | Pancreas | 1 | 2023 | 276 | 0.050 |
Why?
| | Sodium | 1 | 2021 | 184 | 0.040 |
Why?
| | Inpatients | 1 | 2023 | 378 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 81 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 926 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 249 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 35 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2020 | 136 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 251 | 0.040 |
Why?
| | Individuality | 1 | 2019 | 146 | 0.040 |
Why?
| | Skin | 1 | 2022 | 653 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 169 | 0.040 |
Why?
| | United Kingdom | 1 | 2017 | 226 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 507 | 0.030 |
Why?
| | Patient Compliance | 1 | 2020 | 524 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 424 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 552 | 0.030 |
Why?
| | Child, Preschool | 2 | 2019 | 9114 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1836 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2018 | 605 | 0.030 |
Why?
| | Culture | 1 | 2015 | 122 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2014 | 27 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 556 | 0.030 |
Why?
| | Home Care Services | 1 | 2017 | 219 | 0.030 |
Why?
| | Cholecalciferol | 1 | 2014 | 47 | 0.030 |
Why?
| | Parents | 1 | 2021 | 1181 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2272 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 1947 | 0.030 |
Why?
| | Calcifediol | 1 | 2012 | 29 | 0.030 |
Why?
| | Research Design | 1 | 2017 | 919 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 799 | 0.020 |
Why?
| | Tourniquets | 1 | 2011 | 27 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2371 | 0.020 |
Why?
| | Serum Albumin | 1 | 2011 | 137 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 242 | 0.020 |
Why?
| | Infant | 1 | 2019 | 7943 | 0.020 |
Why?
| | Mice | 1 | 2018 | 14841 | 0.010 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|